FMP
Protara Therapeutics, Inc.
TARA
NASDAQ
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
5.39 USD
0.21 (3.9%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Mr. Jesse Shefferman
sector
Healthcare
industry
Biotechnology
website
https://www.protaratx.comexchange
NASDAQ
Description
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
CIK
0001359931
ISIN
US74365U1079
CUSIP
74365U107
Address
345 Park Avenue South
Phone
646 844 0337
Country
US
Employee
26
IPO Date
Oct 22, 2014
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
TARA Financial Summary
CIK
0001359931
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
74365U107
ISIN
US74365U1079
Country
US
Price
5.39
Beta
1.79
Volume Avg.
2.25M
Market Cap
184.98M
Shares
-
52-Week
1.595-10.48
DCF
3.01
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-2.04
P/B
-
Website
https://www.protaratx.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest TARA News
It looks like there's no news available.
